Abstract |
In four patients with Parkinson disease, we compared carbidopa combined with levodopa ( Sinemet) and benserazide combined with levodopa ( Madopar). All of these patients had responded to treatment, first with levodopa and then with Sinemet; after 6 years two continued to show a good response, while two developed marked "on-off" phenomena. Clinically, Sinemet and Madopar were similar; however, DOPA levels were higher, but with a shorter half-life, on Madopar. The higher DOPA levels may have been offset by the shorter half-life, resulting in no clinical change. DOPA levels were lower and half-life was shorter in patients with on-off phenomena. These differences may be responsible in part for the on-off phenomena.
|
Authors | A Lieberman, E Estey, G Gopinathan, T Ohashi, A Sauter, M Goldstein |
Journal | Neurology
(Neurology)
Vol. 28
Issue 9 Pt 1
Pg. 964-8
(Sep 1978)
ISSN: 0028-3878 [Print] United States |
PMID | 567768
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Aromatic Amino Acid Decarboxylase Inhibitors
- Hydrazines
- Dihydroxyphenylalanine
- Benserazide
- Carbidopa
|
Topics |
- Aromatic Amino Acid Decarboxylase Inhibitors
- Benserazide
(therapeutic use)
- Carbidopa
(therapeutic use)
- Dihydroxyphenylalanine
(blood)
- Female
- Humans
- Hydrazines
(therapeutic use)
- Male
- Middle Aged
- Parkinson Disease
(drug therapy)
|